ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bictegravir

Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.

Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.

Drug pageBictegravir: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 23, 202325 company-led studies, 8 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only238 open or runningphase 4since Oct 23, 2023Oct 23, 2014Aug 2027phase 2 · NCT07645287
AGC Biologicsits history only10 open or runningphase 3since Mar 17, 2010Mar 17, 2010none ahead
Merck10 open or runningphase 1since Apr 8, 2026Apr 8, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named bictegravirINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Apr 8, 2026First study: phase 1 study in HealthyFirst studyNCT07532304 · 16 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07532304Healthy · United States1CompletedJul 23, 202616

How it is read

Names in the registry

  • “B/F/TAF”, 16 entries
  • “Bictegravir”, 3 entries
  • “BIC/LEN FDC”, 2 entries
  • “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
  • “Bictegravir/Lenacapavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.